prikaz prve stranice dokumenta HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
  Download
PDF 668.46 KB
Scientific paper - Review paper
HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
International Journal of Molecular Sciences, 24 (2023), 9; 8206. https://doi.org/10.3390/ijms24098206
Popović, Marina; Silovski, Tajana; Križić, Marija; Dedić Plavetić, Natalija

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Popović, M., Silovski, T., Križić, M. & Dedić Plavetić, N. (2023). HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?. International Journal of Molecular Sciences, 24. (9). doi: 10.3390/ijms24098206

Popović, Marina, et al. "HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?." International Journal of Molecular Sciences, vol. 24, no. 9, 2023. https://doi.org/10.3390/ijms24098206

Popović, Marina, Tajana Silovski, Marija Križić and Natalija Dedić Plavetić. "HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?." International Journal of Molecular Sciences 24, no. 9 (2023). https://doi.org/10.3390/ijms24098206

Popović, M., et al. (2023) 'HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?', International Journal of Molecular Sciences, 24(9). doi: 10.3390/ijms24098206

Popović M, Silovski T, Križić M, Dedić Plavetić N. HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?. International Journal of Molecular Sciences [Internet]. 2023 May 04 [cited 2024 May 05];24(9). doi: 10.3390/ijms24098206

M. Popović, T. Silovski, M. Križić and N. Dedić Plavetić, "HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?", International Journal of Molecular Sciences, vol. 24, no. 9, May 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:211367. [Accessed: 05 May 2024]

Metadata
Title (english)HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
AuthorMarina Popović
AuthorTajana Silovski
AuthorMarija Križić
AuthorNatalija Dedić Plavetić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Pathophysiology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathophysiology
Abstract (english)
Despite the great progress made in the understanding of the biological behavior of certain types of invasive breast cancer, there is still no single histological or molecular classification that encompasses such diversity and accurately predicts the clinical course of distinct breast cancer subtypes. The long-lasting classification of breast cancer as HER2-positive vs. HER2-negative has recently come into question with the discovery of new antibody drug conjugates (ADC), which are proven to be remarkably efficient in treating HER2-low breast cancer. The HER2-low paradigm has challenged the traditional understanding of HER2 overexpression and emphasized the need for more robust HER2 testing in order to encompass HER2 intratumoral heterogeneity and spatial distribution more accurately. It is yet to be seen if low HER2 will remain merely a marker of HER2-equipped tumors targetable with ADCs or if distinctive molecular and phenotypic groups within HER2-low tumors will eventually be discerned.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleInternational Journal of Molecular Sciences
Numberingvol. 24, no. 9, 8206
e-ISSN1422-0067
DOIhttps://doi.org/10.3390/ijms24098206
URN:NBNurn:nbn:hr:105:211367
Publication2023-05-04
Document URLhttps://www.mdpi.com/1422-0067/24/9/8206
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2023-11-02 08:56:05